Phase 2 N=10 Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale
Phase 4 N=115 Polidocanol Versus Glucose Treatment of Telangiectasia Trial
Varicose Veins · Telangiectasis
Primary: Change From Baseline in Extent of Telangiectasias — 57.24; 76.08 percent of change negative values
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
N/A N=22 Clinical Evaluation of the Treatment of Spider Angioma
Spider Angioma
Primary: Physician's Global Assessment Scale for Improvement of Spider Angioma — 4.5 score on a scale
Phase 4 N=30 Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
Erythematotelangiectatic Rosacea
Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
N/A N=15 Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata
Cherry Angioma
Primary: Mean Changes in Color, Texture, and Size of Cherry Angiomata From Baseline to 3 Months After the Second Treatment by Treatment Type as Assessed by Blinded Raters — 5.27…
N/A N=24 Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
Poikiloderma of Civatte · Dyschromia · Pigmentation Disorders
Primary: Severity Assessment Score — -0.06; 0.2 score on a scale
Phase 2 N=18 Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis · Hereditary Hemorrhagic Telangiectasia
Primary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale
N/A N=22 Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
Port-Wine Stain
Primary: Percent Change in Blanching of Port Wine Stain — 6; 5 percentage
N/A N=10 Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment
Scarring · Skin Aging
Primary: Study Effectiveness for Skin Aesthetic Improvement — 1.25 score on a scale
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
N/A N=10 Combination Gel and Vascular ND in Mild to Moderate Rosacea
Rosacea
Primary: IGA of Improvement — 3.1; 3.5 units on a scale
N/A N=20 The Effects of Fractional CO2 Laser on Poikiloderma of Civatte
Poikiloderma of Civatte
Primary: Change in Overall Improvement of Poikiloderma of Civatte (POC) From Baseline at 12 Weeks — 11.01; 6.03; 8.51; 5.89 percentage
Phase 3 N=50 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders
Phase 2 N=30 Rosacea and Ivermectin
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
Phase 3 N=449 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
Phase 4 N=47 Nailfold Capillary Blood Flow With Latanoprost Bunod
Glaucoma, Open-Angle
Primary: NFC Blood Flow at Baseline and 15 Minutes — 72.52; 83.94; 93.01; 60.50 pL/s
N/A N=15 Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks
Stretch Marks · Striae Distensae · Cosmetic Appearance of Stretch Marks
Primary: Cosmetic Outcome- Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks — 3; 5 Participants
Phase 2 N=10 Open Label Pilot Study of Apremilast in Treatment of Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98
Phase 2 N=27 Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Assisted Epistaxis Severity Scale (aESS) Score From Baseline at 8 Week Follow-up — 2.32; 1.96 units on a scale
Phase 2 N=20 Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Measurement of Epistaxis in Patients With HHT as Measured by the HHT Foundation Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Ferritin Levels.
N/A N=17 Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains
Port Wine Stains
Primary: Blanching of Port Wine Stain Birthmark — 16 participants
N/A N=45 755nm Alex Laser for Treatment of Stretch Marks
Striae
Primary: Photographic Evaluation of Striae Clearance — 36; 17; 11 areas with striation
Phase 4 N=46 Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
Rosacea
Primary: Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 5; 0 Participants
N/A N=20 Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment
Wrinkle · Rosacea · Scarring
Primary: Global Aesthetic Improvement Scale — 0.95; 1.05 score on a scale
Phase 2 N=34 Effect of CD07805/47 Gel in Rosacea Flushing
Rosacea
Primary: Total Number of Flushes for Each 2-week Period — 15.3; 16.3 Flushes count — p=0.7420
Phase 3 N=445 Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
Erythema · Rosacea
Primary: Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for…
N/A N=20 Broad Band Light for the Treatment and Prevention of Senile Purpura
Senile Purpura · Bateman's Purpura
Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions